In the front‐line setting, secondary EGFR mutation, including C797S, L718Q, G724S, or S768I, were identified in only 6%–10% of plasma samples obtained from NSCLC patients after disease progression, while bypass pathway activation or SCLC transformation were more common.33, 34. This evidence concerns the gene EGFR and non-small cell lung carcinoma.